Kinetics of specific anti-SARS-CoV-2 IgM, IgA, and IgG responses during the first 12 months after SARS-CoV-2 infection: A prospective longitudinal study

• DOI: 10.1371/journal.pone.0288557
• Publication Date: 2023-07-12T18:04:40Z
• Authors: Houda Amellal; Najlaa Assaid; Hicham Charoute; Khadija Akarid; Abderrahmane Maar...; Sayeh Ezzikouri; M’hammed Sarih
• Keywords: Immunoglobulin M; Coronavirus

Coronavirus 2019 (COVID-19) is a global health threat. The kinetics of antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) need to be assessed, as the long-term duration these immunoglobulins remains largely controversial. aim this study was assess longitudinal dynamics anti-SARS-CoV-2 nucleocapsid (N) protein and receptor-binding domain (RBD) spike up one year in cohort 190 COVID-19 patients. Between March September 2021, we enrolled patients from two regional hospitals Casablanca, Morocco. Blood samples were collected analyzed for antibody levels. We used commercial Euroimmun ELISA determination anti-N IgM, Abbott Architect ™ SARS-CoV-2 IgG test detection anti-RBD IgG, an in-house kit assay IgA. IgM IgA assessed 2–5, 9–12, 17–20 32–37 days after symptom onset. also 60, 90, 120 360 One-third developed (32%), while two-thirds (61%). One month onset, most with 97% 93% positivity respectively. rate remained high follow-up. However, decreased over time, only 41% testing positive year’s levels significantly higher older people (over 50 years) than other participants. found that who had received doses ChAdOx1 nCoV-19 vaccine prior infection lower response unvaccinated This difference statistically significant weeks onset symptoms. present first Africa measure (IgA, IgG) year. Most participants seropositive but showed decline titers.